Q3 2017

Latest Quarterly Results
Ended March 31, 2017

$714,889

Research and development YTD

$1,449,080

Net cash used in operations YTD

Stock Snapshot

Propanc Biopharma, Inc. OTCQB: PPCB
Change/Percentage
Day Range
52 Week Range
Volume
Detailed Quote Stock Charts Historical Quote